This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Esbriet

Roche Holding AG

Drug Names(s): pirfenidone, S-7701, Pirespa (Japan), RG6062

Description: Pirfenidone is an orally active small molecule drug. While its mechanism is not completely understood, it inhibits kinase p38 gamma, which affects both transforming growth factor beta (TGF beta, involved in fibrosis) and tumor necrosis factor alpha (involved in inflammation). Pirfenidoneappears to inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines.

Deal Structure: Marnac and Intermune
In March 2002, InterMune licensed from Marnac and its co-licensor KDL, their worldwide rights, excluding Japan, Korea, and Taiwan, to develop and commercialize Pirfenidone for all fibrotic diseases, including renal, liver, and pulmonary fibrosis. Under the terms of this license agreement, InterMune receives an exclusive license from Marnac and KDL in exchange for an up-front cash payment of $18.8 million and future milestone and royalty payments.

In November 2007, InterMune announced that it has entered into agreements with Marnac and with KDL that will eliminate all of InterMune's future royalty and milestone payment obligations for pirfenidone related to the prior license agreement the parties had entered into in March 2002. Under terms of the acquisition agreements, InterMune has made total upfront payments of $13.5 million. Contingent acquisition payments of up to an additional $53.5 million would be made by InterMune only if positive Phase...See full deal structure in Biomedtracker

Partners: KDL GmbH Marnac, Inc. Shionogi & Co. Ltd. Ildong Pharmaceutical Co., Ltd.


Esbriet News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug